Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed and is already licensing DehydraTECH™, a technology that improves the bio-absorption and bioavailability of ingestible substances. A recent article discussing the company’s unique technology reads: “Application of the technology extends beyond nicotine to non-psychoactive cannabinoids, vitamins and non-steroidal anti-inflammatory drugs (NSAIDs), and Lexaria has licensed the … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Continues to Develop Potential Uses of Patented Technology”
Lexaria is ahead of the game in the expected second flow of investment capital in “plant-to-bloodstream” companies Company’s DehydraTECH™ technology has the potential to revolutionize nicotine use, eliminating the major cause of related deaths by shifting demand away from smoking cigarettes DehydraTECH™ makes it possible to experience most of the positives associated with inhalation while … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Ending the Need to Light-Up”
Chris Bunka, CEO of LXRP, in an interview with CFN Media Group, stated that his company’s cash flow is strengthening from licensing and R&D, with technology applicable to other sectors Bunka noted that LXRP’s 71 million share count is kept purposely low relative to others in the category, with its valuation growing by “close to … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Appeals to Investors with Slow Burn Rate, Model that Goes Beyond Cannabis Sector”
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) recently entered into a five-year semi-exclusive licensing agreement with GP Holdings LLC to develop a high performing cannabis beverage to be sold in California, a flourishing cannabis marketplace. A recent article discussing the company’s unique technology reads: “The semi-exclusive agreement gives LXRP the ability to offer other licensee … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Strategically Positioned for Growth in Cannabis Industry”
Lexaria has its patented DehydraTECH™ nutrient infusion technology This technology has patent protection for cannabidiol and all other non-psychoactive cannabinoids DehydraTECH™ technology provides greater bio-absorption Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a worldwide leader in enhancing the gastro-intestinal delivery of edible cannabinoid products. The company has its patented nutrient infusion technology called DehydraTECH™. … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Focusing on Delivery of Bioactive Substances via Oral Ingestion”
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) DehydraTECH™ enables improved bioabsorption and versatility in drug delivery applications. A recent article discussing the company’s unique technology reads: “DehydraTECH™ is a unique enabling technology from Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) that increases the absorption rate of edible ingestion, delivering five to 10 times more of … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Delivers Improved Absorption and Application Versatility”
LXRP, a drug delivery platform innovator, has been awarded two new patent grants in the U.S. and expects three more from Australia Company already has more than 40 patent awards or applications from 40 countries globally; it is preparing new patent application filings and predicts more patent awards this year LXRP received $63,000 from the … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expands Patent Portfolio, Announces Exercise of 450,000 Existing Warrants”
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the U.S. and Australia for utilization of its … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Starts Presentation at the 8th Annual LD Micro Invitational”
Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced its intention to create two wholly owned subsidiaries to hold specific intellectual property. The first subsidiary will hold IP related to the improved processing and combustion-free delivery of nicotine and nicotine analogs, while the second subsidiary will hold IP related to … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Outlines Plans to Create Two Wholly Owned Subsidiaries”
New FDA restrictions on Big Tobacco take effect Tobacco manufacturers turning to ‘reduced-risk’ products No edible nicotine products currently available DehydraTECH improves bio-absorption of nicotine taken orally Smoking may be a dying trend, but consumption of nicotine is not only very much alive; its longevity is assured by Big Tobacco’s foray into alternative tobacco and … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Boosts Prospects for Smoke-Free Nicotine Future”
